Nasdaq · CIK 0001488039
ATOS ATOSSA THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing May 14, 2026. Close $2.44 on Oct 9, 2026, +39% from the 52-week low and -86% from the high.
ATOSSA THERAPEUTICS, INC. (ATOS) has 21 SEC Form 4 filings on file from 9 insiders, the latest filed on May 14, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at ATOS. The newest: Steven C Quay (President & CEO) bought $9,887 of stock on May 21, 2025, filed May 22, 2025, scored 43 (moderate).
ATOS closed at $2.44 on Oct 9, 2026, 39% above its 52-week low and 86% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ATOSSA THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Steven C Quay President & CEO buy | $9,887 11,239 shares | +423% | +47% from low-46% from high | |
| 25Weak | H. Lawrence Remmel director buy | $7,000 10,000 shares | +3891% | - |
Transactions
Every row filed, 23 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | Stephen J Galli director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,006 | May 14, 2026 |
| May 12, 2026 | Jonathan Finn director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 11,666 | May 14, 2026 |
| May 12, 2026 | H. Lawrence Remmel director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,683 | May 14, 2026 |
| May 12, 2026 | Shu-Chih Chen director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | May 14, 2026 |
| May 12, 2026 | Richard I Steinhart director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | May 14, 2026 |
| May 12, 2026 | Tessa Cigler director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | May 14, 2026 |
| Mar 27, 2026 | Steven C Quay President & CEO | AGrant or award Common Stock | +65,000 | $0.00 | $0 | 88,038 | Mar 31, 2026 |
| Mar 26, 2026 | Mark James Daniel Chief Financial Officer | AGrant or award Common Stock | +63,000 | $0.00 | $0 | 63,000 | Mar 30, 2026 |
| Jan 20, 2026 | Steven C Quay President & CEO | AGrant or award Common Stock | +331,674 | $0.00 | $0 | 345,572 | Jan 30, 2026 |
| Jan 20, 2026 | Steven C Quay President & CEO | AGrant or award Stock Options (right to buy)derivative | +950,000 | $0.60 | $573k | 950,000 | Jan 30, 2026 |
| Jan 20, 2026 | Steven C Quay President & CEO | AGrant or award Common Stock | +325,203 | $0.00 | $0 | 339,101 | Jan 22, 2026 |
| Jan 20, 2026 | Steven C Quay President & CEO | AGrant or award Stock Options (right to buy)derivative | +950,000 | $0.60 | $573k | 950,000 | Jan 22, 2026 |
| Oct 14, 2025 | Mark James Daniel Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +578,000 | $0.00 | $0 | 578,000 | Oct 21, 2025 |
| May 21, 2025 | Steven C Quay President & CEO | POpen-market purchase Common Stock | +11,239 | $0.88 | $9,887 | 13,898 | May 22, 2025 |
| May 15, 2025 | Richard I Steinhart director | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| May 15, 2025 | Tessa Cigler director | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| May 15, 2025 | H. Lawrence Remmel director | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| May 15, 2025 | Stephen J Galli director | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| May 15, 2025 | Heather Rees Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +543,785 | $0.00 | $0 | 543,785 | May 16, 2025 |
| May 15, 2025 | Steven C Quay President & CEO | AGrant or award Stock Option (right to buy)derivative | +1,366,062 | $0.00 | $0 | 1,366,062 | May 16, 2025 |
| May 15, 2025 | Shu-Chih Chen director | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| May 15, 2025 | Jonathan Finn director | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| Mar 26, 2025 | H. Lawrence Remmel director | POpen-market purchase Common Stock | +10,000 | $0.70 | $7,000 | 10,257 | Mar 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Shu-Chih Chendirector
- Tessa Ciglerdirector
- Mark James DanielChief Financial Officer
- Jonathan Finndirector
- Stephen J Gallidirector
- Steven C QuayPresident & CEO
- Heather ReesChief Financial Officer
- H. Lawrence Remmeldirector
- Richard I Steinhartcfo, officer, director
Questions about ATOS
Answered from the filings on this page, as of the latest one.
Are insiders buying ATOS?
No. In the last 90 days no insider at ATOSSA THERAPEUTICS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ATOS on the open market?
Steven C Quay (President & CEO) bought $9,887 of ATOS on May 21, 2025 and filed the Form 4 on May 22, 2025. InsiderTell scored 43 (moderate).
How many insiders file Form 4 at ATOSSA THERAPEUTICS, INC.?
9 people have filed a Form 4 at ATOSSA THERAPEUTICS, INC., among them Shu-Chih Chen (director), Tessa Cigler (director), Mark James Daniel (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.